Abstract
Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.
Keywords: FLT3, AML, tyrosine kinase, kinase inhibitor
Related Books
A Journey Through Water: A Scientific Exploration of The Most Anomalous Liquid on Earth
Advances in Anticancer Agents in Medicinal Chemistry
Advances in Anticancer Agents in Medicinal Chemistry
Advances in Combinatorial Chemistry & High Throughput Screening
Advances in Mathematical Chemistry and Applications
Advances in Mathematical Chemistry and Applications
Advances in Mathematical Chemistry and Applications Volume 1 (Revised Edition)
Advances in Organic Synthesis
Advances in Organic Synthesis
Advances in Organic Synthesis